Okogen

About:

Okogenis is a developer of ophthalmic anti-infective drugs.

Top Investors: Brandon Capital, Medical Research Commercialisation Fund (MRCF)

Description:

Okogen serves the needs of adults and children with ocular infections by developing therapies to reduce suffering, improve quality of life, and preserve vision.The company’s efforts are focused on infectious ocular diseases where treatments are either not available or unsatisfactory.

Total Funding Amount:

$16.4M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Encinitas, California, United States

Founded Date:

2015-01-01

Founders:

Bradford Conlan, Brian M Strem, Eric J. Daniels

Number of Employees:

1-10

Last Funding Date:

2024-01-09

IPO Status:

Private

Industries: